Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nonsmall Cell Lung Cancer, Stage IIIB Clear all
Completed Phase 1 Interventional

Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer

NCT00002519
View directory record Official record
Conditions
Lung Cancer
Interventions
chemotherapy, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 19, 2026, 1:36 AM EDT
Completed No phase listed Observational

Study of Tumor Samples From Patients With Lung Cancer

NCT00900328
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00020267
View directory record Official record
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

NCT01999881
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
exercise intervention, standard follow-up care, quality-of-life assessment, laboratory biomarker analysis
Behavioral · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

NCT01000025
View directory record Official record
Conditions
Lung Cancer
Interventions
PF-00299804, Placebo
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Arcadia, California • Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00010023
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00268489
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, pemetrexed disodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
248
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Little Rock, Arkansas + 161 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

NCT01262820
View directory record Official record
Conditions
Lung Cancer
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

NCT00653939
View directory record Official record
Conditions
Tumors
Interventions
Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00100854
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, fulvestrant
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 19, 2026, 1:36 AM EDT
Terminated Phase 1 Interventional Results available

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00288054
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, docetaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
77
States / cities
Anchorage, Alaska • Los Angeles, California • Marysville, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00002656
View directory record Official record
Conditions
Lung Cancer
Interventions
pyrazoloacridine
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 19, 2026, 1:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

NCT00544648
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, nab-paclitaxel, Radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Paducah, Kentucky • Portland, Oregon • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

NCT00017407
View directory record Official record
Conditions
Lung Cancer
Interventions
ISIS 3521, carboplatin, paclitaxel
Biological · Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Carlsbad, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NCT00874848
View directory record Official record
Conditions
NSCLC
Interventions
Imprime PGG Injection, Cetuximab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Augusta, Georgia • Terre Haute, Indiana • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

NCT02879994
View directory record Official record
Conditions
Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 19, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT00061646
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
ABT-510/Thrombospondin-1 mimetic, Carboplatin/Taxol
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Oct 19, 2026, 1:36 AM EDT
Not listed Phase 2 Interventional

Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003562
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer

NCT00002484
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

NCT00398138
View directory record Official record
Conditions
Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions
WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
Biological · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 19, 2026, 1:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abraxane and Alimta in Advanced Solid Tumors

NCT00470548
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Abraxane, Alimta
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

NCT00040885
View directory record Official record
Conditions
Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions
infliximab, docetaxel, placebo
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
188
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 19, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT00126581
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Erlotinib, Erlotinib Hydrochloride, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
96
States / cities
Castro Valley, California • Emeryville, California • Fremont, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 19, 2026, 1:36 AM EDT